^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

AR expression

i
Other names: AR, AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1, Androgen receptor
Entrez ID:
Related biomarkers:
2ms
Looking beyond the ER, PR, and HER2: what's new in the ARsenal for combating breast cancer? (PubMed, Reprod Biol Endocrinol)
This review also raises the possibility of using AR splice variants in predicting tumor aggressiveness. From the settings of developing nations, this may provide useful insight by integrating recent advances in AR-targeted therapies and exploring their translational potential, emphasizing the critical need for further research to optimize AR-based therapeutic strategies for breast cancer management.
Review • Journal • BRCA Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • AR (Androgen receptor)
|
AR positive • AR expression
2ms
Steroid hormone receptors, exome sequencing and treatment responsiveness of breast cancer patient-derived xenografts originated in a South American country. (PubMed, Sci Rep)
BC-AR685 had higher levels of PR isoform A than isoform B and was sensitive to mifepristone, tamoxifen, and palbociclib...BC-AR474 was inhibited by trastuzumab and trastuzumab emtansine. BC-AR485 was sensitive to doxorubicin and resistant to paclitaxel in vivo and ex vivo. BC-AR687 carried a PIK3CA (C420R) mutation and was sensitive to alpelisib and mTOR inhibitors...We report the first PDX originated from South American countries that were genetically and biologically characterized and may be used in precision medicine studies. PDX expressing AR and/or GR are powerful tools to evaluate different endocrine treatment combinations even in TN tumors.
Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
|
EGFR mutation • PIK3CA mutation • HER-2 mutation • AR expression • PIK3CA C420R
|
Ibrance (palbociclib) • paclitaxel • tamoxifen • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Piqray (alpelisib) • Mifeprex (mifepristone)
2ms
Clinical Implications of Breast Cancer Intrinsic Subtypes. (PubMed, Adv Exp Med Biol)
The clinical behavior of HER2-enriched cancers is dominated by the underlying ER subtype. ER+/HER2-enriched cancers tend to have more indolent course and lesser chemotherapy sensitivity than their ER counterparts.
Review • Journal • IO biomarker
|
ER (Estrogen receptor) • AR (Androgen receptor)
|
ER positive • HER-2 amplification • ER negative • AR expression
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
2ms
JARID1D-dependent androgen receptor and JunD signaling activation of osteoclast differentiation inhibits prostate cancer bone metastasis through demethylating H3K4. (PubMed, Theranostics)
Finally, both in vivo and in vitro experiments confirmed that the JARID1D agonist JIB-04 effectively blocked these molecular pathways, thereby delaying the onset of bone metastasis in PCa. These insights provide a theoretical foundation for targeting JARID1D and related molecules in the treatment of PCa bone metastasis.
Journal
|
KDM5D (Lysine Demethylase 5D)
|
AR expression
2ms
Neratinib and the Role of Anti-HER2 Therapy in Salivary Duct Carcinoma. (PubMed, Cancer Rep (Hoboken))
This case confirms the potential efficacy of neratinib in HER2-positive SDC and underlines the need to define the best therapeutic sequence and potential biomarkers for these rare patients.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • AR (Androgen receptor)
|
HER-2 positive • HER-2 overexpression • AR overexpression • AR expression • HER-2 positive + HER-2 overexpression
|
Nerlynx (neratinib)
2ms
Berberine inhibits prostate cancer progression by inducing ferroptosis: evidence from network pharmacology. (PubMed, Anticancer Drugs)
Berberine exhibited cell line-specific effects by reducing AR expression in LNCaP cells and suppressing ICAM1 in PC3 cells. Overall, berberine shows promise in inhibiting prostate cancer progression through modulation of ferroptosis-related genes, including TYMS, AR, CCNB1, AURKA, CDK1, ICAM1, NTRK1, SCD, and CDC42.
Journal
|
NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • TYMS (Thymidylate Synthetase) • AURKA (Aurora kinase A) • ICAM1 (Intercellular adhesion molecule 1) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • CDC42 (Cell Division Cycle 42) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
|
AR expression
2ms
NAB2::STAT6 Rearranged Carcinoma of the Parotid Gland with Sebaceous Differentiation: A Case Report. (PubMed, Head Neck Pathol)
This case further expands the phenotypic spectrum of NAB2::STAT6 rearranged neoplasms and emphasizes comprehensive histopathological and molecular analysis in challenging head and neck tumors. It suggests STAT6 immunohistochemistry as a potential screening tool for head and neck tumors resembling sebaceous carcinoma, myoepithelial tumors, or GLI1-altered neoplasms.
Journal
|
AR (Androgen receptor) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CD34 (CD34 molecule) • GLI1 (GLI Family Zinc Finger 1) • STAT6 (Signal transducer and activator of transcription 6) • NAB2 (NGFI-A Binding Protein 2)
|
AKT1 mutation • AR expression
2ms
Exploring the clinicopathological parameters of HER2 low breast cancers: insights from a retrospective cohort study. (PubMed, Korean J Clin Oncol)
This study underscores the complexity of HER2 low breast cancer and its implications for clinical management, emphasizing the need for personalized treatment strategies. It provides insights into the clinicopathological parameters of HER2 low breast cancers, highlighting their diverse characteristics and clinical implications.
Retrospective data • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • AR (Androgen receptor)
|
HER-2 positive • HR positive • HER-2 overexpression • HER-2 negative • AR expression • HER-2 overexpression + HR positive • HER-2 positive + HER-2 overexpression
|
Herceptin (trastuzumab)
2ms
Androgen receptor overexpression by immunohistochemistry in malignant salivary gland tumors in Tanzania. (PubMed, BMC Cancer)
High-grade malignant SGTs and parotid gland location are associated with AR overexpression. This suggests that androgen deprivation therapy (ADT) has the potential to play a role in the management of advanced SGTs. However, large-scale studies that will include comprehensive molecular investigations and efficacy exploration of ADT are recommended to clarify our current findings and inform therapeutic options for patient with high grade and recurrent tumors.
Retrospective data • Journal
|
AR (Androgen receptor)
|
AR overexpression • AR expression
2ms
Clinical • Retrospective data • Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • AR (Androgen receptor)
|
AR positive • AR expression • ER expression
2ms
Androgen receptor and osteoglycin gene expression predicting prognosis of metastatic prostate cancer. (PubMed, Sci Rep)
The concordance indices for the internal and external validations were 0.664 and 0.798, respectively. In this study, a nomogram that integrated the expression levels of androgen receptors and osteoglycin to predict CSS in metastatic hormone-sensitive prostate cancer was established.
Journal
|
AR (Androgen receptor)
|
AR expression
2ms
Clinicopathological significance of androgen receptor expression and tumor infiltrating lymphocytes in triple-negative breast cancer: a retrospective cohort study. (PubMed, Breast Cancer)
AR/TIL classification using pretreatment biopsies identified TNBC subgroups with distinct NAC responses and prognoses. AR+/TILlow TNBC, including apocrine differentiation cases, were NAC-resistant, highlighting the need for alternative therapies.
Retrospective data • Journal • Tumor-infiltrating lymphocyte
|
AR (Androgen receptor)
|
AR expression
3ms
MUC1 expression is associated with ST3GAL2 and negatively correlated with the androgen receptor in castration-resistant prostate cancer. (PubMed, Glycoconj J)
Our results demonstrate that MUC1 is identified as a ST3GAL2-associated molecule and expressed in AR-negative CRPC cells. Furthermore, level of serum CA15-3 may reflect the progression status of mCRPC.
Journal
|
AR (Androgen receptor) • MUC1 (Mucin 1)
|
MUC1 expression • AR expression
3ms
Detection of the nuclear translocation of androgen receptor using quantitative and automatic cell imaging analysis. (PubMed, Tissue Cell)
The quantitation method to detect nuclear translocation revealed that the AR nuclear signal plateaued approximately 20 min after DHT exposure. Our developed method has the potential to save human labor by the automatic process of the image.
Journal
|
AR (Androgen receptor)
|
AR expression
3ms
Exploring the potential role of ENPP2 in polycystic ovary syndrome and endometrial cancer through bioinformatic analysis. (PubMed, PeerJ)
IF demonstrated that ENPP2 increased the expression of AR, suggesting a regulatory role for ENPP2 in hormonal response within PCOS and EC. Our findings indicated a significant correlation between ENPP2 expression and the modulation of immune responses.
Journal
|
ENPP2 (Ectonucleotide Pyrophosphatase/Phosphodiesterase 2)
|
AR expression
3ms
Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer. (PubMed, Cells)
The recent identification of several other key novel drivers of NE transdifferentiation, including MYCN, ASCL1, BRN2, ONECUT2, and FOXA2, further elucidates the complex regulatory networks and pathways involved in this process. We suggest that, given the multifactorial nature of NEPC, novel therapeutic strategies that combine multiple modalities are essential to overcome therapeutic resistance and improve patient outcomes.
Review • Journal
|
TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • NCAM1 (Neural cell adhesion molecule 1) • SOX2 • FOXA2 (Forkhead Box A2) • SYP (Synaptophysin) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • CHGA (Chromogranin A) • ONECUT2 (One Cut Homeobox 2)
|
AR expression
3ms
Regulation of Stromal Cells by Sex Steroid Hormones in the Breast Cancer Microenvironment. (PubMed, Cancers (Basel))
This review describes how sex steroid hormones, particularly estrogens and androgens, affect stromal cells in the breast cancer microenvironment. We summarize recent findings focusing on the effects of ER/AR signaling in breast cancer cells on stromal cells, as well as the direct effects of ER/AR signaling in stromal cells.
Review • Journal • Stroma
|
ER (Estrogen receptor)
|
ER positive • AR expression
3ms
Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader. (PubMed, Mol Cancer Ther)
Androgen receptor (AR) signaling is the principal driver of prostate cancer, and drugs that target this pathway (e.g., abiraterone and enzalutamide) are standard treatments for metastatic hormone-sensitive prostate cancer and metastatic castration-resistant prostate cancer (mCRPC). These promising preclinical data supported clinical development of bavdegalutamide as a potential treatment for patients with prostate cancer. Bavdegalutamide was the first PROTAC protein degrader to enter human clinical trials, specifically in patients with mCRPC in a phase 1/2 study (NCT03888612).
Preclinical • Journal
|
AR (Androgen receptor) • CRBN (Cereblon)
|
AR expression
|
Xtandi (enzalutamide) • abiraterone acetate • bavdegalutamide (ARV-110)
3ms
Androgen receptor inhibition increases MHC Class I expression and improves immune response in prostate cancer. (PubMed, Cancer Discov)
Mechanistic studies identified androgen response elements upstream of MHCI transcription start sites which increased MHCI expression when deleted. Together, this body of work highlights another mechanism by which hormones can promote immune escape.
Journal • IO biomarker
|
AR (Androgen receptor)
|
AR expression
3ms
Androgen Receptor Influenced Recurrence Score Correlation in Hormone Positive and HER2 Negative Breast Cancer Indian Patients: A Comparative Approach. (PubMed, Genome Integr)
These tools take into consideration the histopathologic parameters and immunohistochemistry (IHC) biomarkers data for estrogen receptor/progesterone (ER/PR), human epidermal growth factor receptor 2 (HER2), and Ki67...No significance was noted across different prediction tools. The findings are suggestive that ME predictive scores are more relevant and informative compared to other online tools and with an additional AR IHC expression analysis the recurrence prediction might prove to be beneficial and feasible to many deprived BC patients.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • AR (Androgen receptor)
|
HER-2 negative • AR expression
|
MammaPrint
3ms
MAGI2-AS3 hypermethylated in promoter region promotes migration and invasion of head and neck squamous cell carcinoma via miRNA-31-5p/AR axis. (PubMed, Transl Oncol)
Thus, MAGI2-AS3 could inhibit the proliferation, migration, and invasion of HNSCC through the miR-31-5p/AR axis. This provided a theoretical basis that MAGI2-AS3 was a potential therapeutic target for HNSCC.
Journal
|
MIR31 (MicroRNA 31) • MAGI2-AS3 (MAGI2 Antisense RNA 3)
|
AR expression
3ms
miR-449, identified through antiandrogen exposure, mitigates functional biomarkers associated with ovarian cancer risk. (PubMed, Sci Rep)
Ovarian cancer cell migration was inhibited upon introducing miR-449a and miR-449b-5p mimics. Together, our study suggests a novel dual-inhibitory mechanism of flutamide on the AR pathway (AR expression suppression in addition to direct androgen antagonism) and supports its chemopreventive potential in ovarian cancer, especially for HR patients with low miR-449 expression.
Journal
|
AR (Androgen receptor) • CSF1R (Colony stimulating factor 1 receptor) • MIR449A (MicroRNA 449a)
|
AR expression
|
flutamide
3ms
Antioxidant, anti-prostate cancer potential, and phytochemical composition of the ethyl acetate stem bark extract of Boascia coriacea (Pax.). (PubMed, PLoS One)
The ethyl acetate stem bark extract of B. coriacea demonstrates significant antioxidant and anticancer activities, potentially through modulation of apoptosis and cell cycle pathways. The presence of bioactive compounds supports its potential as a therapeutic agent, warranting further investigation for developing novel treatments for prostate cancer and oxidative stress-related conditions.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CDK1 (Cyclin-dependent kinase 1)
|
BCL2 expression • AR expression
|
doxorubicin hydrochloride
3ms
Vaccination Against Androgen Receptor Splice Variants to Immunologically Target Prostate Cancer. (PubMed, Vaccines (Basel))
Notably, in this model, we found that vaccination in combination with enzalutamide, an AR antagonist, suppressed these aggressive immune suppressive cancers and resulted in enhanced survival in comparison to control vaccinated and enzalutamide-treated mice. While anti-PD-1 immune checkpoint inhibition (ICI) alone slowed tumor growth, the majority of vaccinated mice that received anti-PD-1 therapy showed complete tumor elimination. Collectively, these results validate the importance of AR signaling in prostate cancer immune suppression and suggest the potential of AR-V7-specific vaccines as therapeutic strategies against prostate cancer, offering significant protective and therapeutic anti-tumor responses, even in the presence of androgen signaling inhibitors.
Journal • PD(L)-1 Biomarker • IO biomarker
|
AR (Androgen receptor)
|
AR expression • AR splice variant 7 • AR-V7 expression • AR splice variant 7 expression
|
Xtandi (enzalutamide)
3ms
Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies. (PubMed, Clin Cancer Res)
We recommend classifying CRPC tumors based on histomorphology (adenocarcinoma, small cell carcinoma, poorly differentiated carcinoma, other morphologic variant, or mixed morphology) and immunohistochemical markers with a priority for AR, NKX3.1, INSM1, synaptophysin and cell proliferation based on Ki-67 positivity, with additional markers to be considered based on the clinical context. Ultimately, a unified workup of metastatic CRPC biopsies can improve clinical trial design and eventually practice.
Journal • Metastases • Biopsy
|
AR (Androgen receptor) • SYP (Synaptophysin) • NKX3-1 (NK3 homeobox 1)
|
AR expression
3ms
Targeting CDK7 enhances the antitumor efficacy of enzalutamide in androgen receptor-positive triple-negative breast cancer by inhibiting c-MYC-mediated tumorigenesis. (PubMed, Mol Cancer Ther)
An enhancement in inhibition of tumor growth and suppression of c-MYC expression was further confirmed when enzalutamide combined with KRLS-017 in an MDA-MB-453 mouse model. Our study suggests that KRLS-017 enhances the antitumor efficacy of enzalutamide by inhibiting c-MYC-mediated tumorigenesis and presents a potential new approach for treating AR+ LAR TNBC.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • AR (Androgen receptor) • CDK7 (Cyclin Dependent Kinase 7)
|
AR positive • MYC expression • AR expression
|
Xtandi (enzalutamide) • KRLS-017
4ms
Recurrent GRHL fusions in a subset of sebaceoma: microscopic and molecular characterisation of eight cases. (PubMed, Histopathology)
In conclusion, we report recurrent fusions of the GRHL genes in a distinctive subset of sebaceomas harbouring infundibulocystic differentiation, a frequent organoid growth pattern and lack of mismatch repair deficiency.
Journal
|
AR (Androgen receptor) • BCL6 (B-cell CLL/lymphoma 6) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2) • BCOR (BCL6 Corepressor) • TP63 (Tumor protein 63)
|
AR expression • MSH6 expression
4ms
Small-molecule disruption of androgen receptor-dependent chromatin clusters. (PubMed, Proc Natl Acad Sci U S A)
Current AR antagonists, such as enzalutamide, fail to provide long-term benefit for the mCRPC patients who have dramatic increases in AR expression...AR binding in the promoter, as well as 3D chromatin clustering, is needed for genes to respond. BG-15a/n represent promising agents for treating patients with relapsed AR-driven mCRPC tumors.
Journal
|
AR (Androgen receptor)
|
AR overexpression • AR expression
|
Xtandi (enzalutamide)
4ms
Analyzing Androgen Receptor Expression in Breast Cancer: Insights into Histopathological Parameters and Hormone Receptor Status Among Indian Women. (PubMed, Indian J Surg Oncol)
AR emerges as a promising marker in breast cancers, particularly in triple-negative cases. Larger-scale studies are warranted to comprehensively assess the relationship between AR expression and histopathological parameters, as well as other immunohistochemical markers.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • AR (Androgen receptor)
|
HER-2 overexpression • AR positive • AR expression • AR negative • PGR expression • PGR negative
4ms
Evaluating the Clinico-Pathological Relationship Between Stromal Tumor-Infiltrating Lymphocytes and Androgen Receptor Expression Across Molecular Subtypes of Invasive Breast Carcinoma. (PubMed, Indian J Surg Oncol)
These findings underscore the complex interplay between AR, TILs, and treatment response in breast cancer, highlighting the potential of personalized therapeutic approaches. Further research is warranted to elucidate the prognostic significance of AR and its implications for tailored treatment strategies in breast cancer management.
Journal • Tumor-infiltrating lymphocyte • Stroma
|
HER-2 (Human epidermal growth factor receptor 2) • AR (Androgen receptor)
|
HER-2 positive • HR positive • AR positive • AR expression • AR negative
4ms
Prognostic role of Androgen Receptor splice variant 7 (AR-V7) in the pathogenesis of breast cancer. (PubMed, BMC Cancer)
Our study unravels AR-V7 as a marker for poor clinical outcomes, predicting breast cancer aggressiveness, and encourages consideration of AR-V7 as a probable target for therapeutic intervention.
Journal
|
AR (Androgen receptor)
|
AR expression • AR splice variant 7 • AR-V7 expression • AR splice variant 7 expression
|
Xtandi (enzalutamide) • bicalutamide
4ms
Unveiling RACK1: a key regulator of the PI3K/AKT pathway in prostate cancer development. (PubMed, Oncogene)
Notably, inhibiting AKT activation via RACK1 deficiency does not trigger feedback upregulation of HER3 and androgen receptor (AR) expression and activation, distinguishing it from direct PI3K or AKT targeting. These findings position RACK1 as a critical regulator of the PI3K/AKT pathway and a promising target for curtailing prostate cancer development arising from pathway aberrations.
Journal
|
PTEN (Phosphatase and tensin homolog) • AR (Androgen receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • RACK1 (Receptor For Activated C Kinase 1)
|
AR expression
4ms
A study of the role of androgen receptor and androgen receptor variant 7 in TNBC patients and the effect of their targeting by Enzalutamide and EPI-001 in MDA-MB-231. (PubMed, J Steroid Biochem Mol Biol)
Molecularly, in MDA-MB-231, both inhibitors modulated metastasis and epithelial to mesenchymal transition (EMT) markers ROCK1, ROCK2, c-Myc, E-cadherin and N-cadherin, with EPI-001 downregulating NF-ĸB level as well. We concluded that ARv7 indicated poor prognosis in the studied cohorts and that blocking of AR/ARv7 abated metastasis and key regulators of EMT in MDA-MB-231, at least in part by targeting ROCK/NF-ĸB/c-Myc axis.
Journal • BRCA Biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • AR (Androgen receptor) • BRCA (Breast cancer early onset) • CDH1 (Cadherin 1) • CDH2 (Cadherin 2)
|
AR expression • AR splice variant 7 • AR-V7 expression • AR-V7 overexpression
|
Xtandi (enzalutamide)
4ms
Effects of time-restricted feeding and weight-loaded swimming test on androgen levels and androgen receptor expression in orchiectomized male Wistar rats. (PubMed, Clin Nutr ESPEN)
IF, PT, and IF+PT demonstrated potential effects on improving androgen levels, managing weight, and enhancing muscle growth, with IF+PT emerging as the most effective intervention. Despite these positive outcomes, the lack of impact on AR expression and testosterone levels suggests the need for further research to elucidate the underlying mechanisms and potential clinical applications for managing androgen deficiency through these interventions.
Preclinical • Journal
|
AR (Androgen receptor)
|
AR expression
4ms
An Autophagy-Targeting Chimera Induces Degradation of Androgen Receptor Mutants and AR-v7 in Castration-Resistant Prostate Cancer. (PubMed, Cancer Res)
Moreover, ATC-324 remains potent in enzalutamide-resistant PCa cells. These results demonstrate the potential of the AUTOTAC platform to target previously considered undruggable proteins and overcome certain drug resistance mechanisms.
Journal
|
AR (Androgen receptor) • SQSTM1 (Sequestosome 1)
|
AR mutation • AR expression • AR splice variant 7 • AR-V7 expression • AR splice variant 7 expression • AR-V7 mutation
|
Xtandi (enzalutamide)
4ms
Androgen receptor expression in recurrent granulosa cell tumor of the ovary: Clinical considerations of treatment and surveillance in a transgender male. (PubMed, Gynecol Oncol Rep)
Although treatment of GCT in transgender individuals has not been well-described, the impact of exogenous hormone use on cancer physiology and treatment should be considered, while also addressing gender dysphoria throughout treatment and in surveillance. Here, we describe a FTM transgender patient with recurrent AR-positive adult granulosa cell tumor after starting testosterone supplementation, along with a literature review to explore the current knowledge of ovarian changes observed following FTM gender transition and subsequent risk of ovarian cancer.
Review • Journal
|
AR (Androgen receptor)
|
AR positive • AR expression
4ms
Correlation of Androgen Receptor Expression With Ki67 Proliferative Index and Other Clinicopathological Characteristics in Invasive Mammary Carcinomas. (PubMed, Cureus)
AR expression may be related to good prognostic factors such as ER expression, PgR expression, and lower histologic grade. We also observed that AR expression did not have any association with the Ki67 proliferative index.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • AR (Androgen receptor)
|
HER-2 expression • AR positive • AR expression • ER expression • AR negative • PGR expression
4ms
EORTC-1206: Androgen Deprivation Therapy in Advanced Salivary Gland Cancer (clinicaltrials.gov)
P2, N=149, Completed, European Organisation for Research and Treatment of Cancer - EORTC | Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Feb 2024
Trial completion • Trial completion date • Metastases
|
AR expression
|
cisplatin • carboplatin • paclitaxel • doxorubicin hydrochloride • bicalutamide • triptorelin
4ms
Decoding the epigenetics and chromatin loop dynamics of androgen receptor-mediated transcription. (PubMed, Nat Commun)
We then propose and experimentally validate an unbalanced multi-enhancer model where the impact on gene expression of AR-bound enhancers is heterogeneous, and is proportional to their contact frequency with target gene promoters. Overall, these findings provide insights into AR-mediated gene expression upon acute androgen simulation and develop a mechanistic framework to investigate nuclear receptor mediated perturbations.
Journal
|
AR (Androgen receptor)
|
AR expression
4ms
Clinicopathological characterized by HER2-low-expressing breast cancer in triple-negative breast cancer (SABCS 2024)
BRCA mutation and PD-L1 positivity are higher in HER2-negative TNBC. Our study revealed that HER2-negative breast cancer has more basal-like clinicopathologic features, while HER2 Low TNBC has non-basal features.
Clinical • PD(L)-1 Biomarker • BRCA Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • AR (Androgen receptor) • BRCA (Breast cancer early onset)
|
HER-2 negative • HER-2 expression • HER-2 underexpression • PD-L1 negative • AR expression • BRCA mutation • PD-L1 expression + HER-2 overexpression
|
VENTANA PD-L1 (SP142) Assay
4ms
Comprehensive characterization of the androgen receptor in male breast cancer (SABCS 2024)
Our analysis suggests a strong association between AR expression and TP53 mutations, TMB-H, and PD-L1 positivity, immune cell infiltration, immune checkpoint and stem cell-related gene. Also, T cell inflamed and IFNy score were inversely related. Further exploration of specific alterations and immune-oncology markers associated with AR expression may help in clinical trial design for male patients with BC.
Tumor mutational burden • PD(L)-1 Biomarker • BRCA Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • AR (Androgen receptor) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • CHEK2 (Checkpoint kinase 2) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD34 (CD34 molecule) • KLF4 (Kruppel-like factor 4) • POU5F1 (POU Class 5 Homeobox 1) • ALDH2 (Aldehyde Dehydrogenase 2 Family Member) • FOXP3 (Forkhead Box P3)
|
TP53 mutation • TMB-H • TP53 wild-type • AR overexpression • AR expression • TP53 expression • FOXP3 expression
|
MI Tumor Seek™
4ms
Molecular landscape of HR+/HER2- male breast cancer (MaBC) compared with female breast cancer (FeBC) (SABCS 2024)
These data indicate that HR+/HER2- MaBC has a differential mutational spectrum and TMB-high frequency, MHC Class I and MHC class II, drug efflux and stem cell-related gene expression compared to their HR+/HER2- FeBC counterparts. These suggest important differences in tumor biology between men and women with HR+/HER2- breast cancer. A better understanding of these differences with additional research may help in design future clinical trials and treatments for men with HR+/HER2- BC.
Tumor mutational burden • PD(L)-1 Biomarker • MSi-H Biomarker • BRCA Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • CDH1 (Cadherin 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • KLF4 (Kruppel-like factor 4) • SOX2 • POU5F1 (POU Class 5 Homeobox 1) • ABCC2 (ATP Binding Cassette Subfamily C Member 2) • ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1) • HLA-B (Major Histocompatibility Complex, Class I, B) • GATA3 (GATA binding protein 3) • PROM1 (Prominin 1) • HLA-DQB2 (Major Histocompatibility Complex, Class II, DQ Beta 2)
|
TMB-H • HR positive • MSI-H/dMMR • HER-2 negative • HER-2 mutation • HER-2 expression • EGFR positive • AR expression
|
PD-L1 IHC 22C3 pharmDx